Advertisement
Advertisement
VNDA
Vanda Pharmaceuticals Inc.
7.22
USDSponsored
+0.10
+1.47%
Mar 27, 11:05 UTC -4
Open
VNDA Earnings Reports
Positive Surprise Ratio
VNDA beat 29 of 39 last estimates.
74%
Next Report
Date of Next Report
May 05, 2026
Estimate for Q1 26 (Revenue/ EPS)
$56.14M
/-$0.72
Implied change from Q4 25 (Revenue/ EPS)
-1.88%
/+56.52%
Implied change from Q1 25 (Revenue/ EPS)
+12.19%
/+44.00%
Vanda Pharmaceuticals Inc. earnings per share and revenue
On Feb 11, 2026, VNDA reported earnings of -0.46 USD per share (EPS) for Q4 25, beating the estimate of -1.35 USD, resulting in a 65.96% surprise. Revenue reached 57.22 million, compared to an expected 60.46 million, with a -5.37% difference. The market reacted with a -17.63% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 5 analysts forecast an EPS of -0.72 USD, with revenue projected to reach 56.14 million USD, implying an increase of 56.52% EPS, and decrease of -1.88% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
Acumen Pharmaceuticals, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.46
Actual
-$0.41
Surprise
+11.29%
Spero Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.20
Actual
$0.53
Surprise
+359.80%
Rani Therapeutics Holdings, Inc. Class A Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.07
Surprise
-2.94%
Alpha Cognition Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.30
Surprise
-8.93%
Cognition Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.02
Surprise
+76.47%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
Quantum Biopharma Ltd. Class B Subordinate Voting Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-Actual
-$0.71
Surprise
-
CollPlant Biotechnologies Ltd Ordinary Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.67
Surprise
-245.72%
FAQ
What were Vanda Pharmaceuticals Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Vanda Pharmaceuticals Inc. reported EPS of -$0.46, beating estimates by 65.96%, and revenue of $57.22M, -5.37% below expectations.
How did the market react to Vanda Pharmaceuticals Inc.'s Q4 2025 earnings?
The stock price moved down -17.63%, changed from $7.43 before the earnings release to $6.12 the day after.
When is Vanda Pharmaceuticals Inc. expected to report next?
The next earning report is scheduled for May 05, 2026.
What are the forecasts for Vanda Pharmaceuticals Inc.'s next earnings report?
Based on 5
analysts, Vanda Pharmaceuticals Inc. is expected to report EPS of -$0.72 and revenue of $56.14M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement